Swiss National Bank boosted its stake in shares of Enanta Pharmaceuticals Inc. (NASDAQ:ENTA) by 35.2% during the second quarter, according to its most recent filing with the SEC. The firm owned 22,300 shares of the company’s stock after buying an additional 5,800 shares during the period. Swiss National Bank owned about 0.12% of Enanta Pharmaceuticals worth $492,000 at the end of the most recent quarter.
A number of other large investors have also recently added to or reduced their stakes in the stock. Adams Diversified Equity Fund Inc. purchased a new stake in Enanta Pharmaceuticals during the second quarter valued at approximately $194,000. Pacad Investment Ltd. boosted its stake in shares of Enanta Pharmaceuticals by 15.3% in the first quarter. Pacad Investment Ltd. now owns 9,800 shares of the company’s stock worth $288,000 after buying an additional 1,300 shares in the last quarter. Schonfeld Strategic Advisors LLC bought a new stake in shares of Enanta Pharmaceuticals during the first quarter worth about $356,000. Jacobs Levy Equity Management Inc. bought a new stake in shares of Enanta Pharmaceuticals during the first quarter worth about $411,000. Finally, Strs Ohio boosted its stake in shares of Enanta Pharmaceuticals by 19.8% in the second quarter. Strs Ohio now owns 29,000 shares of the company’s stock worth $639,000 after buying an additional 4,800 shares in the last quarter. Hedge funds and other institutional investors own 70.70% of the company’s stock.
Enanta Pharmaceuticals Inc. (NASDAQ:ENTA) traded up 0.04% on Monday, hitting $24.12. The company had a trading volume of 42,992 shares. Enanta Pharmaceuticals Inc. has a one year low of $16.75 and a one year high of $41.38. The stock has a market capitalization of $459.12 million, a PE ratio of 15.95 and a beta of 0.52. The stock has a 50 day moving average of $24.67 and a 200-day moving average of $24.85.
Enanta Pharmaceuticals (NASDAQ:ENTA) last released its earnings results on Monday, August 8th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.03. Enanta Pharmaceuticals had a return on equity of 11.31% and a net margin of 32.59%. The business earned $14 million during the quarter, compared to analysts’ expectations of $13.07 million. During the same quarter last year, the firm posted $0.13 earnings per share. The firm’s revenue was up 20.7% on a year-over-year basis. Equities analysts anticipate that Enanta Pharmaceuticals Inc. will post $1.02 EPS for the current year.
ENTA has been the topic of a number of analyst reports. JPMorgan Chase & Co. set a $26.00 price objective on Enanta Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, August 9th. Zacks Investment Research upgraded Enanta Pharmaceuticals from a “hold” rating to a “buy” rating and set a $30.00 price objective on the stock in a research note on Tuesday, September 27th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $27.24.
Enanta Pharmaceuticals Company Profile
Enanta Pharmaceuticals Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create molecule drugs primarily for the treatment of viral infections and liver diseases. The Company is engaged in discovering and developing inhibitors designed for use against the hepatitis C virus (HCV), as well as compounds for non-alcoholic steatohepatitis (NASH) and primary biliary cirrhosis (PBC).
Want to see what other hedge funds are holding ENTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enanta Pharmaceuticals Inc. (NASDAQ:ENTA).
Receive News & Ratings for Enanta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.